In recent findings consistent with results obtained in mice (6, 12), RB1 inactivation has been identified as the only molecular factor independently predictive of poor survival for men with advanced prostate cancer (13, 14), and it likewise decreases overall survival of patients with cancers of the lung, breast, and bladder (15–17). Here, RB1 is linked to prostate carcinoma.